Medicines for Specific Cancers (E through L)

Drugs Approved for Endometrial Cancer

Lenvatinib
Megestrol
Pembrolizumab

Drugs Approved for Esophageal Cancer

Docetaxel
Nivolumab
Pembrolizumab
Ramucirumab
Trastuzumab
Trifluridine and Tipiracil

Drugs Approved for Gastrointestinal Stromal Tumors

Avapritinib
Imatinib
Regorafenib
Ripretinib
Sunitinib

Drugs Approved for Gestational Trophoblastic Disease

Dactinomycin
Methotrexate
Vinblastine

Drugs Approved for Head and Neck Cancer

Bleomycin
Cetuximab
Docetaxel
Hydroxyurea
Methotrexate
Nivolumab
Pembrolizumab

Drugs Approved for Hodgkin’s Disease

Bleomycin
Brentuximab Vedotin
Carmustine
Chlorambucil
Cyclophosphamide
Dacarbazine
Dexamethasone
Doxorubicin
Lomustine
Mechlorethamine
Nivolumab
Pembrolizumab
Prednisone
Procarbazine
Vinblastine
Vincristine

Drugs Approved for Kaposi Sarcoma

Doxorubicin
Paclitaxel
Interferon
Paclitaxel
Vinblastine

Drugs Approved for Kidney (Renal Cell) Cancer

Aldesleukin
Avelumab
Axitinib
Bevacizumab
Cabozantinib
Everolimus
Ipilimumab
Lenvatinib
Mitomycin
Nivolumab
Pazopanib
Pembrolizumab
Sorafenib
Sunitinib
Temsirolimus
Tivozanib

Drugs Approved for Acute Myeloid leukemia (AML)

Asparaginase
Blinatumomab
Calaspargase Pegol-mknl
Clofarabine
Cyclophosphamide
Cytarabine
Dasatinib
Daunorubicin
Dexamethasone
Doxorubicin
Imatinib
Inotuzumab Ozogamicin
Mercaptopurine
Methotrexate
Nelarabine
Pegaspargase
Ponatinib
Prednisone
Tisagenlecleucel
Vincristine

Drugs Approved for Acute Lymphoblastic Leukemia (ALL)

Arsenic Trioxide
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Enasidenib
Gemtuzumab
Gilteritinib
Glasdegib
Idarubicin
Ivosidenib
Midostaurin
Mitoxantrone
Thioguanine
Venetoclax
Vincristine

Drugs Approved for Chronic Myeloid Leukemia (CML)

Bosutinib
Busulfan
Cyclophosphamide
Cytarabine
Dasatinib
Dexamethasone
Hydroxyurea
Imatinib
Nilotinib
Omacetaxine
Ponatinib

Drugs Approved for Chronic Lymphocytic Leukemia (CLL)

Acalabrutinib
Alemtuzumab
Bendamustine
Chlorambucil
Cyclophosphamide
Dexamethasone
Duvelisib
Fludarabine
Ibrutinib
Idelalisib
Obinutuzumab
Ofatumumab
Prednisone
Rituximab
Venetoclax

Drugs Approved for Hairy Cell Leukemia

Cladribine
Interferon
Moxetumomab

Drugs Approved for Mast Cell Leukemia

Midostaurin

Drugs Approved for Meningeal Leukemia

Cytarabine

Drugs Approved for Liver Cancer

Atezolizumab
Bevacizumab
Cabozantinib
Lenvatinib
Nivolumab
Pembrolizumab
Pemigatinib
Ramucirumab
Regorafenib
Sorafenib

Drugs Approved for Non-Small Cell Lung Cancer

Alectinib
Atezolizumab
Bevacizumab
Brigatinib
Capmatinib
Carboplatin
Ceritinib
Crizotinib
Dabrafenib
Dacomitinib
Docetaxel
Doxorubicin
Durvalumab
Entrectinib
Erlotinib
Everolimus
Gefitinib
Gemcitabine
Ipilimumab
Lorlatinib
Methotrexate
Necitumumab
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab
Pemetrexed
Pralsetinib
Ramucirumab
Selpercatinib
Tepotinib
Trametinib

Drugs Approved for Small Cell Lung Cancer

Atezolizumab
Doxorubicin
Durvalumab
Etoposide
Everolimus
Lurbinectedin
Methotrexate
Nivolumab
Pembrolizumab

Other Cancers

Medicines Approved for Specific Cancers (A-D)

Medicines Approved for Specific Cancers (M-Z)

Chemo agents for specific cancers in PDF format.